Allergan has announced restructuring, which includes staff reductions of 1,000 employees in commercial and other functions, the elimination of 400 open positions, and other cost-cutting actions. Read More

Roche and Ignyta, a biopharmaceutical company, have signed a merger agreement under which Roche will acquire Ignyta for $27.00 per share or approximately $1.7 billion.   Read More

Mallinckrodt , a specialty pharmaceutical company, has agreed to acquire Sucampo Pharmaceuticals, a biopharmaceutical company, for $1.2 billion. Read More

Pfizer and Arvinas, a biotechnology company, have signed an agreement worth up to $830 million for developing drug candidates using Arvinas’ proprietary platform for creating small-molecule therapeutics aimed at degrading disease-causing cellular proteins. Read More

FDA Commissioner Scott Gottlieb has issued an update on the agency’s effort to support manufacturing in Puerto Rico following Hurricanes Irma and Maria, particularly regarding saline shortages. Read More

Impax Laboratories, a specialty pharmaceutical company focused on controlled-release and specialty generics, has agreed to sell its manufacturing facility in Taiwan to Bora Pharmaceuticals, a Taiwanese pharmaceutical company, as part of plans to streamline operations and reduce costs. Read More

The FDA has issued draft guidance to streamline aspects of the submission and review process for generic-drug applications (i.e., abbreviated new drug applications [ANDAs]). The agency also published a companion document, a Manual of Policies and Procedures, to assist the agency’s staff. Read More

Recipharm, a Jordbro, Sweden-based CDMO, has agreed to acquire the remaining 26% stake in Nitin Lifesciences, an Indian sterile injectables contract manufacturing organization (CMO), making it wholly owned by Recipharm. Read More

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued to Apotex, a generic-drug company, a statement of non-compliance with GMPs for its solid-dosage manufacturing facility in Bangalore, India . Read More

The FDA has issued a Warning Letter for cGMP violations for finished pharmaceuticals to Fresenius Kabi, a specialty and generic pharmaceuticals company and a subsidiary of Fresenius KGaA, a healthcare group, for its drug-manufacturing facility in Baddi, India . Read More